<DOC>
	<DOCNO>NCT00628433</DOCNO>
	<brief_summary>The purpose pilot , exploratory study evaluate safety , tolerance , pharmacokinetics potential activity investigational agent , HE3286 , administer orally , daily 28 day patient mild-to-moderate ulcerative colitis .</brief_summary>
	<brief_title>Safety Pharmacokinetics Study HE3286 Patients With Active , Mild-to-Moderate Ulcerative Colitis</brief_title>
	<detailed_description>HE3286 potentially new mechanism action may improve current therapeutic option available patient ulcerative colitis . In preclinical experiment , HE3286 show activity animal model ulcerative colitis . Additionally , HE3286 show anti-inflammatory activity associate corticosteroid without side effect associate corticosteroid use , immune suppression bone loss .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>1865 year age Diagnosed ( &gt; 6 week ) recently relapse active mildtomoderate ulcerative colitis base colonoscopy flexible sigmoidoscopy Mayo Scoring System Assessment Ulcerative Colitis Activity score 49 Stable dose prior screen 6mercaptopurine ( 50150 mg/day 6MP ) [ least 2 month ] , Azathioprine ( 50100 mg/day ) [ least 2 month ] , 5ASA [ least 2 week ] For female reproductive potential , agree avoid pregnancy study 3 month follow study completion , negative serum pregnancy test ( bHCG ) screen negative urine pregnancy test use acceptable method birth control No history narcotic and/or alcohol abuse within 2 year screen agrees consume &lt; 6 oz . wine equivalent per day No experience renal liver disease history and/or base laboratory result Must provide voluntary , write , informed consent prior screen evaluation able follow verbal write instruction Must able swallow capsule Primary sclerosing cholangitis Positive C. difficile toxin stool Requires hospitalization treatment severe ulcerative colitis History clinically significant cardiovascular disease ( include coronary artery disease ) , clinically significant hepatic , respiratory renal abnormality , clinically significant endocrine disorder ( include diabetes ) Clinically significant abnormality laboratory result ( renal insufficiency , liver function abnormality , abnormal WBC ANC ) Any clinically significant unstable medical abnormality , chronic disease , active , serious clinical infection condition , ulcerative colitis Uncontrolled hypertension define systolic BP &gt; 160 mmHg and/or diastolic BP &gt; 100 mmHg three assessment one day ( blood pressure must stable &gt; 3 month prior screen ) Malignancy within past 5 year , except successfully treat basal cell carcinoma skin Requiring receive antiTNFa immune modulate drug ( 6MP azathioprine ) within 8 week prior screen Requiring receive follow within 4 week screen visit : interleukin , steroid ( i.e. , anabolic steroid , glucocorticoid ) , narcotic , anticancer chemotherapeutic agent , metabolic inhibitor nutraceuticals immune enhancement claim Requiring oral intravenous cortisone Requiring corticosteroid enema Acute illness within 10 day prior Day 1 take antibiotic UC ( infectious disease ) within 14 day Day 1 Any clinical condition receive therapy , opinion Investigator , would make patient unsuitable study unable comply dosing requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>phase I/II</keyword>
	<keyword>ulcerative colitis</keyword>
	<keyword>safety</keyword>
	<keyword>tolerance</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>